Viewing nowCombinationLifomin Duo Sustained Release Tablet 2.5/1000 mg (Linagliptin, Metformin Hydrochloride)
Metformin Hydrochloride 1000mg · Linagliptin Micronized 2.5mg
Tablet · Prescription medication · Combination
Daehan New Pharm Co., Ltd.

MFDS item code 202400614 · Approved 2024.03.22 · Insurance code 669908380
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication helps patients with type 2 diabetes manage their blood sugar levels more effectively when combined with dietary and exercise therapy. Linagliptin and metformin work together to help improve blood sugar levels. Therefore, this medication is used to enhance blood glucose control in type 2 diabetes.
The dose of this medication for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg. This medication should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain its extended-release properties, this medication should be swallowed whole and not split, crushed, ground, or chewed. The 5/1000 mg extended-release tablet of this medication should be taken once daily as 1 tablet per dose. Patients taking the 2.5/1000 mg extended-release tablets of this medication should take 2 tablets together once daily. 1. Patients not currently receiving metformin: The initial dose of this medication is a total daily dose of linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this medication is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this medication consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this medication is administered concomitantly with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this medication, the dose of this medication is the patient's current dose of linagliptin and extended-release metformin hydrochloride. Special populations Renal impairment Because dose adjustment according to renal function is necessary, assessment of renal function is recommended before starting this medication and periodically during treatment. No dose adjustment of this medication is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), with creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, who tolerate treatment well and have no other conditions that may increase the risk of lactic acidosis, this medication may be used with adjustment of the metformin hydrochloride dose as follows. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medication. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) falls below 45mL/min or estimated glomerular filtration rate (eGFR) falls below 45mL/min/1.73m2, this medication should be discontinued immediately.
This medication is a diabetes treatment consisting of metformin and linagliptin. It can rarely cause a serious condition called lactic acidosis, so it is not to be administered to patients with impaired kidney function or acute illnesses. Also, this medication should not be used by individuals allergic to its components or by patients with type 1 diabetes, acute pancreatitis, and others. During treatment with this medication, hypoglycemic symptoms may occur, especially when taken with other hypoglycemic agents such as insulin or sulfonylureas, so attention is needed. Patients with reduced kidney function or the elderly should regularly check their kidney function during treatment, and if kidney function falls below a certain level, this medication should be discontinued. It should be temporarily stopped in situations affecting kidney function, such as acute illnesses, surgery, or radiologic tests. If symptoms such as abdominal pain, weakness, or difficulty breathing occur during treatment, consult a doctor immediately as these may be signs of lactic acidosis. This medication may cause gastrointestinal disturbances, diarrhea, nausea, vomiting, etc., so it is advisable to take it during or after meals. Long-term use may lead to vitamin B12 deficiency, so testing vitamin B12 levels is necessary if anemia or neurological symptoms arise. It is preferred to avoid taking this medication during pregnancy or breastfeeding, and it is essential to consult a doctor if planning to become pregnant or if already pregnant. Do not crush or chew this medication; swallow it whole, and the tablet shell may appear in feces, which is normal. When taken with other medications, there is a possibility of interaction, particularly with drugs affecting kidney function or blood sugar, so follow your doctor's instructions. The effects on driving or operating machinery are unclear, so caution is required. In case of overdose, there is a risk of lactic acidosis, so seek immediate medical attention for appropriate treatment. This medication should be stored in a tightly closed container to avoid moisture and should be kept out of the reach of children, and it is advisable not to transfer to other containers.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air and moisture from entering, at room temperature between 1 to 30 degrees Celsius. Storing it this way will maintain the effectiveness and ensure safe use of the medication.
Oval sustained-release tablet, white to almost white, engraved with DN21 on one side
28 tablets/box [7 tablets/PTP x 4], 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationMetformin Hydrochloride 1000mg · Linagliptin Micronized 2.5mg
Tablet · Prescription medication · Combination
Daehan New Pharm Co., Ltd.
Linagliptin Micronized 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Samjin Pharmaceutical Co., Ltd.
Linagliptin Micronized 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Samjin Pharmaceutical Co., Ltd.
Linagliptin Micronized 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Samjin Pharmaceutical Co., Ltd.
CombinationLinagliptin Micronized 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
CombinationLinagliptin Micronized 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
CombinationLinagliptin Micronized 5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
CombinationLinagliptin Micronized 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.